Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 15;7(4):ofaa130.
doi: 10.1093/ofid/ofaa130. eCollection 2020 Apr.

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

Katelyn A Pastick  1 , Elizabeth C Okafor  1 , Fan Wang  2 , Sarah M Lofgren  1 , Caleb P Skipper  1 , Melanie R Nicol  2 , Matthew F Pullen  1 , Radha Rajasingham  1 , Emily G McDonald  3 , Todd C Lee  3 , Ilan S Schwartz  4 , Lauren E Kelly  5 , Sylvain A Lother  6 , Oriol Mitjà  7 , Emili Letang  8   9 , Mahsa Abassi  1 , David R Boulware  1
Affiliations
Review

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

Katelyn A Pastick et al. Open Forum Infect Dis. .

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.

Keywords: COVID-19; Hydroxychloroquine; SARS-CoV-2; chloroquine; clinical trials; coronavirus.

PubMed Disclaimer

Comment in

References

    1. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report - 75. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2.... Accessed 4 April 2020.
    1. NIH U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/ Accessed 4 April 2020.
    1. Kim AHJ, Sparks JA, Liew JW, et al. . A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med 2020; In Press. - PMC - PubMed
    1. Tönnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy - a review of the literature. Immunopharmacol Immunotoxicol 2013; 35:434–42. - PubMed
    1. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42:145–53. - PMC - PubMed